UK Medical Device Certification for Bleepa

Reach announcement

Feedback plc

Bleepa affixed with a UK Medical Device Certification (UKCA)

·      UKCA regulatory certification further validates Bleepa technology

London, 29 June 2021: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, today announces that a UKCA mark, the post-BREXIT UK regulatory certification, has been affixed to Bleepa, Feedback's flagship medical imaging communications platform, adding to its portfolio of regulatory approvals for Bleepa.

Dr Tom Oakley, CEO of Feedback, commented:

"In addition to the CE mark affixed last year, Bleepa has now enhanced its regulatory technical file to include the UK's medical Device Manufacturing mark.  The new UK product marking is used for goods being placed on the market in Great Britain post-BREXIT and further validates as well as provides confidence in the quality and expertise of Bleepa's technology."

Enquiries:

Notes to Editors

Feedback plc (AIM: FDBK) is a medical imaging technology business. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go. 

Its highly scalable Software as a Service ("SaaS")-based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care facilitators. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of diagnosis.

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.